Markets

Kalaris Therapeutics Announces Additional Data From Its Phase 1A Trial Of TH103 In Neovascular Age-Related Macular Degeneration; Additional Patients Showed Improvements In Vision And Retinal Anatomy

Jul 17, 2026 · 07:05 AM ET· updated 11h ago

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced

Why It Matters

Kalaris shared good news that more patients in their eye-disease medicine test got better vision and healthier eye parts. When a medicine company shows that more patients improve, it's a sign their medicine might actually work, so it's worth watching how the test continues.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.